title: Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma.
abstract: OBJECTIVE
  To evaluate the effects of carteolol hydrochloride (carteolol) on 24-h variations in intraocular pressure (IOP) in patients with normal-tension glaucoma (NTG).
  
  
  METHODS
  Twelve patients with NTG were treated with carteolol 2% solution for >or=8 weeks; their pretreatment 24-h IOP variations, blood pressure (BP), and pulse rate (PR) were compared with those measured after the treatment period.
  
  
  RESULTS
  Daytime IOP (at 07:00, 10:00, 13:00, and 16:00), maximum IOP, and the mean 24-h IOP were significantly reduced after treatment, as was the 24-h IOP range. Systolic BP in the morning and both systolic and diastolic BP in the afternoon were significantly decreased by the treatment, whereas no significant change of PR was observed.
  
  
  CONCLUSIONS
  Carteolol had no effect on nocturnal IOP but significantly helped reduce daytime IOP, maximum IOP, mean 24-h IOP, and the 24-h IOP range. The drug exerted no statistically significant effect on the PR.
authors.affiliation: Department of Ophthalmology, Tokyo Metropolitan Police Hospital, Nakano-ku, Tokyo, Japan. user902850@aol.com
authors.forename: Kenji
authors.initials: K
authors.lastname: Nakamoto
authors.forename: Noriko
authors.initials: N
authors.lastname: Yasuda
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage*; D001794:Blood Pressure / Q000187:drug effects; D002354:Carteolol / Q000008:administration & dosage*; D002940:Circadian Rhythm / Q000187:drug effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D057066:Low Tension Glaucoma / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D014065:Tonometry, Ocular
chemical_list: D000319:Adrenergic beta-Antagonists; D009883:Ophthalmic Solutions; D002354:Carteolol
references.citation: Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2566-73
references.pmid: 10937568
references.citation: Am J Ophthalmol. 1998 Oct;126(4):487-97
references.pmid: 9780093
references.citation: Nippon Ganka Gakkai Zasshi. 1997 Mar;101(3):227-31
references.pmid: 9086741
references.citation: J Pharmacol Exp Ther. 1988 Nov;247(2):590-5
references.pmid: 2903235
references.citation: Br J Clin Pharmacol. 1982;13(Suppl 2):245S-257S
references.pmid: 6125175
references.citation: Nippon Ganka Gakkai Zasshi. 2004 Jul;108(7):401-7
references.pmid: 15359902
references.citation: Am J Ophthalmol. 1997 Oct;124(4):498-505
references.pmid: 9323940
references.citation: Zhonghua Yi Xue Za Zhi (Taipei). 2001 Oct;64(10):575-80
references.pmid: 11791944
references.citation: J Glaucoma. 1994 Winter;3(4):339-45
references.pmid: 19920620
references.citation: J Glaucoma. 2000 Apr;9(2):134-42
references.pmid: 10782622
references.citation: J Glaucoma. 2000 Feb;9(1):45-50
references.pmid: 10708231
references.citation: Am J Ophthalmol. 1997 Apr;123(4):465-77
references.pmid: 9124243
references.citation: Ophthalmology. 1993 May;100(5):643-50
references.pmid: 8493005
references.citation: Nippon Ganka Gakkai Zasshi. 2003 Jul;107(7):375-9
references.pmid: 12894744
references.citation: Graefes Arch Clin Exp Ophthalmol. 1991;229(3):258-61
references.pmid: 1869063